Standardize and Streamline the Process Around Ordering Lung Cancer Biomarker Tests

<table>
<thead>
<tr>
<th>Problem Statement</th>
<th>Root Causes</th>
</tr>
</thead>
</table>
| To reduce variability and improve efficiencies, there is a need to standardize and streamline the process around ordering lung cancer biomarker tests | ● Oncologists have different attitudes and preferences around: when to order biomarker testing; which tests to order; which lab to use for testing  
● There is no standardized biomarker testing protocol within the practice  
● The EHR lacks a templated biomarker test ordering process |

Baseline Measurement:

- Review how biomarker testing was ordered for patients with stage IV NSCLC from 2019
- Create a spreadsheet that includes the following:
  - When was the order placed?
  - Which tests were ordered?
  - Which lab performed the testing?
  - How long did it take for the results?
- Look for patterns or trends in the data: Where are the biggest variations?

Exploratory questions:

- Which labs are used most often?
- Are oncologists willing to use a single lab?
- What impact does health insurance have on lab selection?
- How complex and burdensome is the prior authorization process?
- What types of turnaround time do the various labs provide for these tests?
Discuss causes and effects:

Aim Statement (example):

- Establish a standardized NSCLC biomarker testing process that will reduce variation in lab selection by <xx>.

Potential Solutions

- Create a process map that shows how biomarker tests are ordered
- Identify which laboratory vendors will perform the testing
- Coordinate with billing around network coverage and prior authorization requirements
- Optimize the workflow by standardizing key elements and creating templated order sets

This data collection sheet is a resource from the ACCC educational initiative, Fostering Excellence in Care and Outcomes in Patients with Stage III/IV NSCLC.